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Abstract
Background: We report age-dependent penetrance estimates for leucine-rich repeat kinase 2
(LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most frequently seen
LRRK2 mutation, Gly2019Ser (G2019S), is associated with approximately 5 to 6% of familial PD
cases and 1 to 2% of idiopathic cases, making it the most common known genetic cause of PD.
Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly
due to differences in study design and recruitment, including in particular differences between
samples of familial PD versus sporadic PD.
Methods: A sample, including 903 affected and 58 unaffected members from 509 families
ascertained for having two or more PD-affected members, 126 randomly ascertained PD patients
and 197 controls, was screened for five different LRRK2 mutations. Penetrance was estimated in
families of LRRK2 carriers with consideration of the inherent bias towards increased penetrance in
a familial sample.
Results: Thirty-one out of 509 families with multiple cases of PD (6.1%) were found to have 58
LRRK2 mutation carriers (6.4%). Twenty-nine of the 31 families had G2019S mutations while two
had R1441C mutations. No mutations were identified among controls or unaffected relatives of PD
cases. Nine PD-affected relatives of G2019S carriers did not carry the LRRK2 mutation themselves.
At the maximum observed age range of 90 to 94 years, the unbiased estimated penetrance was 67%
for G2019S families, compared with a baseline PD risk of 17% seen in the non-LRRK2-related PD
families.
Conclusion: Lifetime penetrance of LRRK2 estimated in the unascertained relatives of multiplex
PD families is greater than that reported in studies of sporadically ascertained LRRK2 cases,
suggesting that inherited susceptibility factors may modify the penetrance of LRRK2 mutations. In
addition, the presence of nine PD phenocopies in the LRRK2 families suggests that these
susceptibility factors may also increase the risk of non-LRRK2-related PD. No differences in
penetrance were found between men and women, suggesting that the factors that influence
penetrance for LRRK2 carriers are independent of the factors which increase PD prevalence in men.

Background
Parkinson's disease (PD) is a neurodegenerative disorder,
affecting approximately 1.8% of individuals over the age
of 65 [1]. Some cases of PD are due to known genetic or
environmental factors but most are likely due to complex
interactions among unidentified genes and environmental risk factors. These susceptibility factors may also play a
role in the penetrance of known PD genes.
Mutations in the leucine-rich repeat kinase 2 gene
(LRRK2) are the most common known genetic cause of
PD. The most frequent LRRK2 mutation, G2019S, is estimated to be associated with 5% to 6% of familial PD and
1% to 2% of idiopathic cases in populations of European
descent [2,3]. More than 20 additional rare mutations

throughout the LRRK2 gene have been reported with varying frequency among different populations [2].
Studies of the G2019S mutation have reported a wide
range of penetrance estimates. Early studies, performed in
large families with multiple affected members, reported
high lifetime penetrance for LRRK2 mutations, ranging
from 70% [4] to 100% [5]. Subsequent studies of the agedependent penetrance of G2019S mutations in families
with multiple affected members have reported a range of
penetrance estimates. Kachergus and colleagues [6]
reported 17% penetrance at age 50 increasing to 85% at
age 70 in 13 families segregating the G2019S mutation,
while Lesage and colleagues [7] reported 33% penetrance
at age 50, increasing to 100% at age 75 in 13 French and
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North African families ascertained for dominantly inherited PD.
More recent studies have screened ethnically diverse PD
populations, who were not ascertained for familial history
of the disease. These studies have generally reported lower
lifetime penetrance estimates for the G2019S mutation,
ranging from 22% to 32% [8-10], and decreased agedependent penetrance ranging from 2% at age 50 to 33%
at age 80 [11]. One possible explanation for the higher
penetrance estimates reported among the family-based
LRRK2 studies is an ascertainment bias created by more
ready ascertainment of families with multiple affected
members. Alternatively, genetic or environmental susceptibility factors shared by affected family members may
also increase penetrance in some families.
In this study, we report age-dependent penetrance estimates for LRRK2 derived from a large sample of familial
PD with consideration of the potential for bias inherent in
a familial sample. Penetrance was estimated for families
with either the G2019S or R1441C mutations, as well as
for the G2019S mutation alone.

der specialist. When possible, the affection status of other
family members was also confirmed by neurological
examination. In cases where examination was not possible (for example, where the affected family member was
deceased) PD affection status was determined through
administration of a diagnostic questionnaire (adapted
from Marder et al, estimated sensitivity = 95.5% and specificity = 96.2% [12]). Family history data was collected in
a structured interview which collected information on the
onset age and PD affection status for all first-degree relatives of the proband.
Genotyping
Genotyping of the G2019S, R1441C, R1441H, Y1699C
and I2020T mutations was performed using TaqMan technology implemented on the ABI PRISM® 7900 HT
Sequence Detection system (Applied Biosystems: Foster
City, CA) for 650 familial PD cases, 126 randomly ascertained PD cases, 125 controls and 30 unaffected relatives
of familial PD cases. The mutations G2019S and R1441C,
the only mutations observed in the initial sample size
above, were typed in an additional 253 familial PD cases,
72 controls and 28 unaffected relatives of familial PD
cases.

Methods
Subjects
Study participants were recruited by the GenePD study, an
international multi-site study of the genetics of PD, using
three ascertainment strategies: 1) PD-affected probands
with a PD-affected sibling; 2) PD-affected probands with
a PD-affected parent or offspring; and 3) PD-affected
probands with another PD-affected relative such as a
cousin, aunt or uncle. Both affected and unaffected relatives of the proband were recruited (Table 1). An additional series of 126 randomly ascertained PD cases was
recruited through the BUMC/BU Neurology Associates
clinic. Controls were recruited from the spouses or in-laws
of PD patients at BUMC/BU Neurology Associates clinic
and from four GenePD study site clinics. All participants
gave informed consent and the study was approved by the
Boston University Medical Center Institutional Review
Board.

The diagnostic criteria for PD affection follow the United
Kingdom Brain Bank criteria, and all probands were
examined by a neurologist trained as a movement disor-

All variants identified by allelic discrimination assays
were further confirmed by directly sequencing PCR products, which was performed by the DNA sequencing core at
Massachusetts General Hospital using an ABI377/XL or an
ABI3730 DNA analyzer. Forward and reverse primers were
used with Applied Biosystems BigDye terminator v3.1
sequencing chemistry according to the manufacturer's
protocol.
Estimation of penetrance
Family history data for PD affection, age at onset and age
at death were used to assess penetrance among the parents
of sibships ascertained for at least two PD-affected siblings
where at least one of these was determined to be a LRRK2
carrier. Only the parents from families ascertained as
affected sibling pairs were used in this analysis, in order to
avoid bias towards increased penetrance among those
families ascertained as PD-affected parent-offspring pairs.
Similarly, the siblings in these sibships themselves were
not used in the assessment of penetrance, in order to
avoid the bias of ascertainment of sibships with multiple

Table 1: Distribution by sex and mean ages of onset or enrollment for the idiopathic Parkinson's disease (PD), familial PD, unaffected
PD relative and controls samples

Randomly ascertained PD
Familial PD
Unaffected relatives
Controls

N

Men (%)

Women (%)

Mean age at onset or *enrollment

126
903
59
197

81 (64%)
501 (55%)
26 (44%)
95 (48%)

45 (36%)
402 (45%)
33 (56%)
102 (52%)

56.3
60.4
*58.7
*65.9
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affected members. The parents of PD-affected siblings
were used to provide an unbiased sample in which to estimate penetrance because the likelihood of PD-affected
siblings being ascertained into the study is independent of
the affection status of their parents.
Penetrance estimates were made under the assumption
that only one parent from each LRRK2 sibship was a carrier. Because nearly all the parents were deceased, it was
not possible to determine which parent was the mutation
carrier. Thus, one parent per sibship was selected as the
LRRK2-carrying parent using the following criteria. In
families where neither parent was PD-affected, one parent
was selected at random. When one parent was PDaffected, selection was weighted to select the affected parent 98.5% of the time and the unaffected parent 1.5% of
the time, to allow for the presence of PD phenocopies
among affected parents. This weighting was derived from
a conservative estimate of an underlying population prevalence of PD of 1.5% for the age range of the study sample. This selection process was repeated 1000 times, each
time randomly selecting one LRRK2 carrier parent according to the above criteria, to produce a distribution of survival estimates for PD. Final penetrance estimates were the
average of the 1000 penetrance estimates.
The PROC LIFETEST procedure in SAS v9.1 was used to
produce the product-limit survival estimates for each
event (for example PD onset) or censoring age. Penetrance
was calculated for each age by subtracting the survival estimate from 1. The same estimation was performed in the
set of non-LRRK2 carrying families ascertained as affected
sibling pairs to permit a comparison of the age-dependent
penetrance of LRRK2 families with the age-dependent risk
of PD in families of unspecified etiology.
Differences in LRRK2 penetrance by sex were examined by
testing the homogeneity of the survival curves for men
and women using the Log-rank test for each of the 1000
randomly selected samples.

Results
From the 903 familial PD cases studied, 58 LRRK2 mutation carriers (6.4%) were identified in 31 apparently unrelated families (Table 2). Four R1441C mutation carriers
were identified in two families, while the remaining 54
carriers had G2019S mutations. Six G2019S mutations
were identified in the 126 randomly ascertained PD cases
(4.8%). No mutations were identified among the controls
or unaffected relatives of PD cases. Nine PD-affected relatives of G2019S carriers did not carry the LRRK2 mutation
themselves, suggesting that some multiplex families have
multiple sources of PD and that PD phenocopies are
found among LRRK2 families.
The majority of families in this study were recruited as
affected sibling pairs (401 of 509 families or 79%), and
6% of these were LRRK2 families (Table 2). Comparatively, 8% of the affected parent-offspring-ascertained
families were LRRK2 families and none of the families
ascertained through more distantly related affected relative pairs included LRRK2 carriers.
The average ages of onset of PD in LRRK2 carriers and
non-carriers are shown in Table 3. There were no significant differences in onset age between LRRK2 carriers and
non-carriers, between carriers of different types of LRRK2
mutations, or between men and women.
Family history data from 22 of the 24 families carrying
LRRK2 mutations and 340 of the 377 of non-LRRK2 families ascertained through the affected sibling pair method
was available for estimation of penetrance of the LRRK2
mutations. Age-dependent penetrance was estimated in
22 of 24 families carrying LRRK2 mutations ascertained
through the affected sibling pair method and separately in
20 of the 22 families carrying the G2019S data (two families had incomplete family history data). The two families carrying the R1441C mutation were not analyzed
separately due to the small sample size. The age -dependent penetrance of PD among the parents of non-LRRK2
families ascertained by the affected sibling pair method
was estimated to provide a baseline risk for comparison.

Table 2: Subjects are presented according to the method of ascertainment, with the number of unaffected relatives genotyped for
LRRK2 mutations shown in parenthesis

Ascertainment method

Subjects (unaffected relatives)

Families

LRRK2 mutations (%)

LRRK2 families (%)

903 (58)
730 (37)
141 (20)
32 (1)

509
401
88
20

58 (6.4%)
47 (6.4%)
11 (7.8%)
0

31 (6.1%)
24 (6.0%)
7 (8.0%)
0

126
197

126
197

6 (4.8%)
0

6 (4.8%)
0

Total familial Parkinson's disease cases and families studied
• Affected siblings
• Affected parent-offspring
• Other affected relatives
Randomly ascertained PD
Controls
No controls or unaffected family members were determined to be LRRK2 carriers.
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Table 3: Mean onset ages stratified by LRRK2 mutations and sex are shown

G2019S
Women

Men
No. of cases (%)
Mean onset age
No. of familial cases (%)
Mean onset age
No. of idiopathic cases (%)
Mean onset age

32 (53.3%)
60.0
29 (53.7%)
59.9
3 (50%)
61.0

28 (46.7%)
59.9
25 (46.3%)
59.3
3 (50%)
64.3

R1441C
Men

Women

Men

No LRRK2 mutations
Women

1 (25%)
53.0
1 (25%)
53.0
0
-

3 (75%)
67.0
3 (75%)
67.0
0
-

549 (56.9%)
60.0
471 (55.7%)
60.9
78 (65.0%)
55.0

416 (43.1%)
59.7
374 (44.3%)
59.9
42 (35.0%)
57.7

No significant differences in onset age were detected in any category.

0.9
0.8

PENETRANCE

0.7
0.6
0.5

LRRK2

0.4
0.3
NON-LRRK2

0.2
0.1
0

90

85

80

75

70

65

60

55

50

45

4
-9

9
-8

4
-8

9
-7

4
-7

9
-6

4
-6

9
-5

4
-5

9
-4

9

4
-4

-3

40

0

AGE RANGE
th and 75
th percentiles
Figure
disease-affected
The
etrance
box1
atplot
each
shows
age
siblings
range
the median
for G2019S
and 25carriers
and
for non-LRRK2
with carriers
whiskersamong
extending
families
to the
recruited
5th andfor
95thatpercentiles
least two Parkinson's
of the penThe box plot shows the median and 25th and 75th percentiles with whiskers extending to the 5th and 95th percentiles of the penetrance at each age range for G2019S carriers and for non-LRRK2 carriers among families
recruited for at least two Parkinson's disease-affected siblings.
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The median, quartiles and 5th and 95th percentile of the
penetrance calculated in 1000 random selections of a single parent from each G2019S family are shown in Figure
1. In order to provide a baseline for comparison, the agedependent risk of PD in parents of non-LRRK2 PDaffected siblings is also shown. In the age range of 50 to
54, the median estimated penetrance is 10% among the
G2019S carriers, compared with 1% in non-LRRK2 carriers. At the maximum observed onset age range (90 to 94
years), the median estimated penetrance reaches 67% for
the parents in G2019S mutation families, approximately
four times greater than the expected risk in parents of nonLRRK2 PD-affected siblings. Including the R1441C families (data not shown) increases the maximum observed
penetrance to 70%.
There was no observed difference in penetrance between
fathers and mothers; none of the 1000 log-rank tests
showed a significant difference in penetrance by sex (data
not shown).

http://www.biomedcentral.com/1741-7015/6/32

selected to include multiple affected members (for example 'familial PD') with penetrance in families with a single
affected member (for example 'sporadic' or 'idiopathic'
PD) will, by definition, generate lower estimates in the latter group if the multiple affected members required for
selection in the former group are included in the estimates. We sought to avoid this bias towards inflated penetrance by studying only the parents of subjects who were
recruited as sibling pairs. Nonetheless, the comparison of
estimates across these different study designs indicates
variability in LRRK2 penetrance among families. This suggests the presence of other genetic factors which modify
the actions of LRRK2 mutations and influence the penetrance. Mutations in LRRK2 have been associated with not
only typical PD but with other pathologies as well [3]. The
questionnaires used for this study do encompass other
disorders but are most specifically designed to identify
likely PD cases. Therefore these estimates should be considered only as estimates of the penetrance of typical PD
and may underestimate the penetrance of any manifestation of LRRK2-related pathology.

Discussion
LRRK2 mutations were identified in both randomly ascertained idiopathic PD cases and in families with multiple
PD-affected members. As expected, LRRK2 mutations
were more common among families with multiple cases
of PD than in randomly ascertained cases and more common in families recruited as parent-offspring pairs with an
apparent dominant transmission than in those recruited
as affected sibling pairs. The number of mutations identified in cases with no family or parental history of PD
(4.8%) is consistent with previous reports of G2019S
LRRK2 mutations.
The R1441C mutation was only observed in two sets of
siblings, both of whom reported a parental history of PD
and at least one other PD-affected relative. While this pattern of affection is suggestive of full penetrance for this
mutation, the sample is too small to justify this inference
with confidence. Future studies of a larger group of
R1441C and other LRRK2 mutations may provide interesting insights into the mechanisms of LRRK2-related PD
through comparison of the age-dependent penetrance
among the different LRRK2 mutations and their modifiers.
The more common G2019S mutation shows reduced penetrance in this sample of familial PD. However the penetrance estimated here, in a sample composed entirely of
familial PD, is substantially higher than that reported previously in a sample of randomly ascertained idiopathic
PD cases (67% versus 33% at age 85 [11]). Conversely,
studies of G2019S in large familial samples [4-7] report
higher penetrance (70 to 100% at age 75) than the 67% at
age 85 reported here. Contrasting penetrance in families

A positive family history of PD is associated with
increased risk of PD [13] and the 17% risk among parents
of PD sibling pairs in non-LRRK2 families is higher than
the risk expected in the general population (see Figure 1).
Genetic factors which influence the penetrance of LRRK2
mutations may either interact only with that gene or may
be factors which influence the susceptibility to familial
PD among non-LRRK2 carriers as well. The presence of
nine phenocopies identified among the relatives of
G2019S carriers suggests that at least some genetic susceptibility factors are common to both LRRK2 and nonLRRK2-related PD.
No significant difference in penetrance was seen between
fathers and mothers, although men are at a generally
higher risk of PD than women [14]. This suggests the possibility that modifiers of LRRK2 penetrance are independent from the sex-dependent modifiers of PD risk in
general. Similarly however, no significant difference in
penetrance was seen between fathers and mothers of the
affected sibling pairs of non-LRRK2 families, which is
more surprising, given that this sample is predominantly
male (see Table 3). These two findings suggest that sexdependent modifiers of PD risk may have a reduced effect
in both LRRK2 and non-LRRK2-related familial PD, relative to that seen in sporadic or idiopathic PD. This is consistent with a recent study in a large Ashkenazi sample
which also suggested that the risk of LRRK2-related PD is
similar in men and women as opposed to the risk of idiopathic PD which was increased in men [15].
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Conclusion
While the PD penetrance estimate of 67% for LRRK2
mutation families is four times that seen in non-LRRK2related PD families, these studies suggest that there is a
significant level of non-penetrance among LRRK2 carriers.
Additionally, the presence of phenocopies and the
increased penetrance in PD families compared with randomly ascertained PD samples suggest genetic susceptibility factors which affect risk of both LRRK2-related and
idiopathic PD. Thus, identification of the factors which
influence penetrance may hasten discovery of diseasemodifying factors in both LRRK2 families as well as in idiopathic PD.
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